Key Insights

Highlights

Success Rate

74% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

20.0%

5 terminated out of 25 trials

Success Rate

73.7%

-12.8% vs benchmark

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

64%

9 of 14 completed with results

Key Signals

9 with results74% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (6)
P 2 (8)
P 3 (2)
P 4 (1)

Trial Status

Completed14
Terminated5
Unknown2
Withdrawn2
Active Not Recruiting1
Recruiting1

Trial Success Rate

73.7%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT02870738Phase 2Active Not RecruitingPrimary

Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

NCT06299683Not ApplicableRecruiting

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT05260112Not ApplicableCompletedPrimary

Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide

NCT01613586Phase 2CompletedPrimary

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

NCT00661050WithdrawnPrimary

Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi

NCT04275297Not ApplicableCompleted

Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT02214550Phase 4CompletedPrimary

Chronic Pain Risk Associated With Menstrual Period Pain

NCT05752344CompletedPrimary

Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era

NCT01060254Phase 2TerminatedPrimary

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

NCT00999518Phase 2TerminatedPrimary

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00601484Phase 2CompletedPrimary

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00275379Not ApplicableWithdrawnPrimary

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

NCT00672087Completed

Diagnostic Challenges in IC (and Male CPPS)

NCT02787083Phase 3TerminatedPrimary

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis

NCT02781103Not ApplicableTerminatedPrimary

Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain

NCT02395042Phase 2CompletedPrimary

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

NCT02497976Phase 3CompletedPrimary

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02411110Phase 2CompletedPrimary

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

NCT00675298Completed

Linkage Analysis in Interstitial Cystitis

NCT02868775UnknownPrimary

A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome

Scroll to load more

Research Network

Activity Timeline